The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Preventing and managing infections in patients with lymphoma treated with immunosuppressive therapy
Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia, discusses the prevention and management of infections in patients with lymphoma treated with immunosuppressive therapies, such as bispecific antibodies. Prof. Hawkes emphasizes the importance of sufficient antimicrobial prophylaxis and monitoring patients for viral reactivation. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
